ADVFN - Advanced Financial Network.
HOME» NASDAQ » M » MYL Stock Price » MYL Stock News

Mylan Inc. Share News

 Mylan Inc. (mm) Stock Price
MYL Stock Price
 Mylan Inc. (mm) Stock Chart
MYL Stock Chart
 Mylan Inc. (mm) Stock News
MYL Stock News
 Mylan Inc. (mm) Company Information
MYL Company Information
 Mylan Inc. (mm) Stock Trades
MYL Stock Trades

US Judge Upholds Validity Of Merck's Vytorin Patent

By Peter Loftus Of DOW JONES NEWSWIRES A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (MRK) Vytorin cholesterol-lowering drug, which could stave off competing generic copies for several years. In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said a patent for Vytorin was valid and enforceable. Merck, based in Whitehouse Station, N.J., said in a recent regulatory filing it expects its U.S. exclusivity for Vytorin and a related drug, Zetia, to expire in April 2017. Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell a generic version of Vytorin before its patent protection expired, arguing that the patent was invalid and unenforceable. Schering-Plough, which was acquired by Merck in 2009, filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's product. A trial was held in December 2011, leading to Judge Linares's opinion Friday. On a conference call with analysts Friday morning, Merck Chief Executive Kenneth Frazier said he was anticipating a favorable decision. "We believe this is a patent that is valid and enforceable," he said. A Mylan spokeswoman couldn't immediately be reached. Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million. Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval. -By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

Stock News for Mylan Inc. (MYL)
DateTimeHeadline
06/24/201619:01:25Statement of Changes in Beneficial Ownership (4)
06/24/201617:12:44Filing of Certain Prospectuses and Communications in Connection...
06/24/201617:02:20Current Report Filing (8-k)
06/24/201611:44:00Mylan Launches Generic Avodart® Capsules
06/23/201611:22:00Mylan Donates €1 Million to the Princess Máxima Center for Pe...
06/20/201617:17:23Filing of Certain Prospectuses and Communications in Connection...
06/20/201609:54:00Attorney General Rejects VEB's Request Regarding Mylan Shareholder...
06/17/201608:00:00Drugs - Generic Stocks Technical Data - Allergan, Mylan, Horizon...
06/17/201606:01:39Notice of Effectiveness (effect)
06/16/201617:18:02Filing of Certain Prospectuses and Communications in Connection...
06/16/201616:35:00Mylan to Commence Meda Offer on June 17
06/16/201616:35:00Mylan to Commence Meda Offer on June 17
06/15/201617:14:32Current Report Filing (8-k)
06/15/201617:12:41Filing of Certain Prospectuses and Communications in Connection...
06/15/201613:47:00Mylan Completes Acquisition of Renaissance's Leading Topicals-Focused...
06/14/201608:41:54Registration Statement for Securities to Be Issued in Business...
06/08/201619:03:17Statement of Changes in Beneficial Ownership (4)
06/08/201619:01:26Initial Statement of Beneficial Ownership (3)
06/06/201610:32:21Statement of Changes in Beneficial Ownership (4)
06/03/201618:00:00Study Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer...

Mylan Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad